A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.
||Peter Kozuch, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
This study is for subject with diagnosed esophageal cancer. This study will help to test whether the addition of the drug trastuzumab to standard treatment with chemotherapy and surgery can help prevent your cancer from growing back. Trastuzumab is a drug that’s effective in certain esophageal cancers that have increased HER2 expression. HER2 is a special gene or protein in a cell. Trastuzumab is proven to reduce breast cancer from growing back. However, the use of trastuzumab for esophageal cancer is experimental and needs to be investigated further.
- Male and female of at least 18 years old
- Pathologically confirmed primary adenocarcinoma of the esophagus
- HER2 positive esophageal cancer
- Must have endoscopy with biopsy
- Prior therapy with trastuzumab not eligible
- Prior radiation for esophageal cancer or prior chest radiotherapy not eligible
- Subjects with cervical esophageal cancer not eligible
- Pregnant or nursing women not eligible
Please call for more information.